Tennessee Oncology, PLLC

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Metastatic breast cancer4 trials
• Lung cancer3 trials
• Cervical cancer1 trial
• Colorectal cancer1 trial
• Liver and biliary tract cancer1 trial
• Melanoma1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 24 trials
• Phase 34 trials
• Phase 1/21 trial

Status

• Active, not recruiting4 trials
• Completed4 trials
• Terminated1 trial

Lead sponsor

• Pfizer6 trials
• Seagen, a wholly owned subsidiary of Pfizer3 trials

Running trials

• Active, not recruiting

  A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

  NCT05132582· Phase 3· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma

  NCT04657991· Phase 3· Pfizer· Source

• Active, not recruiting

  Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

  NCT04579380· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Active, not recruiting

  A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

  NCT03052608· Phase 3· Pfizer· Source

Closed trials

• Completed

  A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer

  NCT04539938· Phase 2· Seagen, a wholly owned subsidiary of Pfizer· Source

• Terminated

  Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)

  NCT04585815· Phase 1/2· Pfizer· Source

• Completed

  Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer

  NCT02007512· Phase 2· Pfizer· Source

• Completed

  Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

  NCT01889238· Phase 2· Pfizer· Source

• Completed

  A Study of Palbociclib (PD-0332991) + Letrozole vs. Letrozole For 1st Line Treatment Of Postmenopausal Women With ER+/HER2- Advanced Breast Cancer (PALOMA-2)

  NCT01740427· Phase 3· Pfizer· Source